http://eon.businesswire.com/news/eon...brain/clinical

For those of you following (and participating!) in the PPMI study, this recently paper uses data generated from the study. As you may recall, this story has been established to validate lead biomarker candidates. The data collected (from 400 PD patients and 200 controls) is extensive -- biosamples, clinical measures, neuroimaging. Importantly, the study was designed so that as data was collecting during the study, it would be made available real time --- this is exactly what is happening.

The study is STILL RECRUITING but some subjects have been in the story for over a year (I'm a control and just had my 3rd LP last week so in one year, they have quite a bit of data from participants). A data portal was created to enable scientists worldwide access to all the data. Since the portal went live, over 26,000 downloads have already taken place. The PPMI database www.ppmi-info.org is a literal gold mine.

Look for more and more progress on identifying these critical markers. All very exciting!

Debi

KineMed to Present Ground-*‐Breaking Human Biomarker Data for the Diagnosis and Treatment of Parkinson’s Disease.

http://www.kinemed.com/Media/PRESS_R..._Sept_2012.pdf

I didn't think we would see results so soon - I can't believe it - so exciting!

You just made my year!

Let me clarify/correct myself...apparently this grant was funded through our ongoing biomarker discovery efforts. While we have launched PPMI to validate markers that have achieved a certain level of data/justification we have maintained additional, parallel investments in finding novel biomarkers. The discovery portfolio could source candidates that could ultimately be flipped into the PPMI study infrastructure. So, I misspoke about this study already being within the PPMI world.

The Kinemed finding is a proof of concept (PD vs control). We are funding the next step (looking cross-sectionally -- do the distinctions hold in early vs mid vs late-stage PD). If the biomarkers still hold, then this would be a candidate for use of PPMI data/samples.

Still exciting but wanted to correct my statement.

Debi

Do you have any idea when this study is expected to come with conclusive results ?

Please disabuse me of my mis perception--but who cares if bio markers can diagnose you early on when 1. There is no med to slow progression and 2. An extra-early diagnosis will only give the insurance ce companies the opportunity to find you uninsurable.

If you scan the link in the original post you will see that they can now see at a molecular level how our neuronal axis is impaired. They then have applied some sort of remedy or booster and it resulted in slowing progression or reversal of symptoms.

I was fairly skeptical of biomarkers too but this is beyond what I ever expected in just identifying one measly marker :P

Laura

Every PD patient has its own progression of PD. In clinical trials as conducted right now, because of this it is very difficult to find out if an agent is neuroprotective. A biomarker is the solution to this problem. So Arsippe, this is a very important result.